The impact of F-18 PSMA PET imaging on clinical decision-making in prostate cancer across disease states.

Authors

null

Ali Arafa

University of MInnesota, Minneapolis, MN

Ali Arafa , Aditya Jain , Brad Humphrey , Jerry Froelich , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Diagnostics and Imaging

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 63)

DOI

10.1200/JCO.2023.41.6_suppl.63

Abstract #

63

Poster Bd #

B17

Abstract Disclosures

Similar Posters

Poster

2023 ASCO Genitourinary Cancers Symposium

<sup>18</sup>F-DCFPyL PET in first BCR and initial staging: Concordance with conventional imaging.

18F-DCFPyL PET in first BCR and initial staging: Concordance with conventional imaging.

First Author: Miles Hsu

First Author: Michael Leapman

Poster

2024 ASCO Genitourinary Cancers Symposium

Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).

Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC).

First Author: Frederic Pouliot

Poster

2024 ASCO Genitourinary Cancers Symposium

Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.

Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.

First Author: Ahmed M. Mahmoud